Clindamycin Phosphate Solution
NDC 45802-562
Product Information
Clindamycin Phosphate is a ANDA-approved product labeled by Padagis Israel Pharmaceuticals Ltd. This medication is used to treat acne. It is supplied as a solution for topical administration. This product entry covers the primary NDC 45802-562 and 4 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 45802-562?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CLINDAMYCIN PHOSPHATE (UNII: EH6D7113I8)
- CLINDAMYCIN (UNII: 3U02EL437C) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ISOPROPYL ALCOHOL (UNII: ND2M416302)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- WATER (UNII: 059QF0KO0R)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 309333 - clindamycin phosphate 1 % Topical Solution
- RxCUI: 309333 - clindamycin 10 MG/ML Topical Solution
- RxCUI: 309333 - clindamycin (as clindamycin phosphate) 1 % Topical Solution
- RxCUI: 309333 - clindamycin 1 % Topical Solution
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Clindamycin Topical
Topical clindamycin is used to treat acne. Clindamycin is in a class of medications called lincomycin antibiotics. It works by slowing or stopping the growth of bacteria that cause acne and by decreasing swelling.
[Learn More]
* Please review the full disclaimer at the bottom of this page.